BSG and colorectal cancer: Boye et al. [177] suggest that CD147 could be used in the selection of stage III patients for adjuvant therapy for colorectal cancer, and Yang et al. [98] showed that CD147 expression is associated with poor overall survival in patients with glioblastoma and suggest that CD147 may be used to detect treatment response in glioblastoma patients.